Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Silo Pharma (SILO) EBIT (2016 - 2025)

Historic EBIT for Silo Pharma (SILO) over the last 13 years, with Q3 2025 value amounting to -$1.2 million.

  • Silo Pharma's EBIT fell 1400.03% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.3 million, marking a year-over-year decrease of 3085.31%. This contributed to the annual value of -$4.7 million for FY2024, which is 2204.85% down from last year.
  • According to the latest figures from Q3 2025, Silo Pharma's EBIT is -$1.2 million, which was down 1400.03% from -$1.2 million recorded in Q2 2025.
  • Silo Pharma's 5-year EBIT high stood at -$436849.0 for Q2 2021, and its period low was -$1.8 million during Q4 2024.
  • Over the past 5 years, Silo Pharma's median EBIT value was -$949154.0 (recorded in 2022), while the average stood at -$969864.4.
  • The largest annual percentage gain for Silo Pharma's EBIT in the last 5 years was 5617.02% (2021), contrasted with its biggest fall of 46547.9% (2021).
  • Over the past 5 years, Silo Pharma's EBIT (Quarter) stood at -$942416.0 in 2021, then plummeted by 75.82% to -$1.7 million in 2022, then rose by 29.77% to -$1.2 million in 2023, then tumbled by 55.82% to -$1.8 million in 2024, then skyrocketed by 36.5% to -$1.2 million in 2025.
  • Its last three reported values are -$1.2 million in Q3 2025, -$1.2 million for Q2 2025, and -$1.1 million during Q1 2025.